返回 Agenda
Session 5: Emerging EU HTA - Will Joint Scientific Consultations and Joint Clinical Assessments on the European level enable faster and broader patient access to ATMPs?
Session Chair(s)
Vanessa Elisabeth Schaub
Global Access Senior Health Systems Strategy Leader HTA & Reimbursement
F. Hoffmann-La Roche, Switzerland
Topics covered in this session include:
- What is the EC’s vision for accelerated patient access in Europe by moving to a European HTA approach?
- How a flexible yet predictable should HTA approach for ATMPs look like?
- Will JSC help early alignment for non-traditional evidence requirements and needs?
- Which role will RWE & Registries play along the product life cycle to close data gaps?
Speaker(s)
Emil Andrei Cochino, MD, MHS
European Medicines Agency, Netherlands
Scientific Senior Specialist (Risk Management)
Marcus Guardian
EUnetHTA, Netherlands
COO EUnetHTA 21, General Manager - Heads of HTA Agencies Group
Maria João Garcia, PharmD
F. Hoffmann-La Roche, Ltd., Switzerland
Global Access Evidence Lead